Evommune, Inc. (EVMN)
NYSE:EVMN
Want to see EVMN full AI Analyst Report?
Top Page
Evommune, Inc.
(NYSE:EVMN)
Select Model
Select Model
Rating:47Neutral
Price Target:
$22.00
▼(-19.85% Downside)
Action:Reiterated
Date:06/03/26
The score is primarily held back by weak financial performance driven by large ongoing losses and accelerating cash burn, despite meaningful balance-sheet de-risking and strong revenue growth. Technicals are also soft (below key moving averages with negative MACD). Corporate updates are supportive around pipeline progress and financing, but valuation remains constrained by unprofitability.
Positive Factors
Strengthened balance sheet
A major recapitalization flipped equity to $205.6M and cut debt nearly to zero, materially reducing leverage and solvency risk. This durable balance-sheet repair provides financing optionality to fund mid-stage development, support partnerships, and absorb execution variance over the coming years.
Negative Factors
Accelerating cash burn
Operating and free cash flow have deteriorated materially, reflecting rising R&D and operating spend. The accelerating cash burn implies ongoing financing need unless costs drop or revenues scale, creating dilution and execution risk that can pressure strategic flexibility over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthened balance sheet
A major recapitalization flipped equity to $205.6M and cut debt nearly to zero, materially reducing leverage and solvency risk. This durable balance-sheet repair provides financing optionality to fund mid-stage development, support partnerships, and absorb execution variance over the coming years.
Read all positive factors
Evommune, Inc. (EVMN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$713.88M
Dividend YieldN/A
Average Volume (3M)935.27K
Price to Earnings (P/E)―
Beta (1Y)0.08
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees45
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,018,370
10 Day Avg. Volume412,591
30 Day Avg. Volume935,274
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.63
Price to Sales (P/S)41.51
P/FCF Ratio-7.04
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue28.98
Enterprise Value/Gross Profit31.25
Enterprise Value/Ebitda-3.66
Forecast
1Y Price Target
$52.00Price Target Upside89.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Evommune, Inc. Business Overview & Revenue Model
Company Description
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urti...
How the Company Makes Money
null...
Evommune, Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 10.00M | 13.00M | 7.00M | 5.00M |
| Gross Profit | 9.28M | 13.00M | 5.71M | 4.00M |
| EBITDA | -79.20M | -79.68M | -65.49M | -32.99M |
| Net Income | -75.99M | -68.87M | -66.81M | -34.05M |
Balance Sheet | ||||
| Total Assets | 322.45M | 224.95M | 76.06M | 82.25M |
| Cash, Cash Equivalents and Short-Term Investments | 211.46M | 149.20M | 72.04M | 79.08M |
| Total Debt | 9.11M | 2.06M | 193.31M | 150.63M |
| Total Liabilities | 17.90M | 19.38M | 220.29M | 159.96M |
| Stockholders Equity | 304.56M | 205.57M | -144.24M | -77.71M |
Cash Flow | ||||
| Free Cash Flow | -80.36M | -76.68M | -58.28M | -30.09M |
| Operating Cash Flow | -80.05M | -76.44M | -58.20M | -29.97M |
| Investing Cash Flow | -214.17M | -115.31M | -3.99M | -48.43M |
| Financing Cash Flow | 338.03M | 220.76M | 49.42M | 63.75M |
Evommune, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $563.98M | -3.96 | -42.57% | ― | 80.00% | 25.18% | |
52 Neutral | $1.47B | -2.91 | -53.31% | ― | 213.96% | 25.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $217.44M | -2.76 | -36.55% | ― | -67.73% | -11.57% | |
48 Neutral | $453.62M | -5.99 | -9999.00% | ― | -1.26% | -23.97% | |
47 Neutral | $713.88M | -8.78 | -195.15% | ― | ― | ― | |
41 Neutral | $527.59M | -2.99 | -106.22% | ― | -9.42% | -67.60% |
* Healthcare Sector Average
EVMN
Evommune, Inc.
19.82
-0.41
-2.03%
ALT
Altimmune
2.90
-2.52
-46.49%
ARCT
Arcturus Therapeutics
7.65
-5.35
-41.15%
OCGN
Ocugen
1.34
0.49
57.46%
VIR
Vir Biotechnology
8.74
3.51
67.11%
VALN
Valneva
5.63
-0.57
-9.19%
Evommune, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
Evommune Stockholders Reelect Directors and Ratify Auditor
Positive
Jun 2, 2026
On June 2, 2026, Evommune, Inc. held its 2026 Annual Meeting of Stockholders, where a quorum was present and shareholders elected directors Luis Peña and Eugene Bauer, M.D., to serve on the board until the 2029 annual meeting or until success...
Business Operations and StrategyFinancial Disclosures
Evommune Highlights Q1 Results and Advancing Inflammation Pipeline
Positive
May 7, 2026
Evommune, Inc., a clinical-stage biotech specializing in therapies for chronic inflammatory diseases such as atopic dermatitis, chronic urticaria and related conditions, reported first quarter 2026 financial results and detailed progress across it...
Business Operations and StrategyProduct-Related Announcements
Evommune Spotlights EVO756 as Novel Preventive Migraine Therapy
Positive
Apr 13, 2026
On April 13, 2026, Evommune hosted a webcast detailing the migraine treatment landscape and presenting MRGPRX2 inhibition, via its oral small-molecule candidate EVO756, as a novel approach to address neuroinflammatory and mast cell drivers of migr...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Evommune Reports Q4 2025 Results and Pipeline Progress
Positive
Mar 5, 2026
Evommune, Inc. reported its fourth quarter and full-year 2025 results on March 5, 2026, highlighting positive Phase 2a proof-of-concept data for its injectable IL-18 binding protein fusion protein EVO301 in moderate-to-severe atopic dermatitis, wi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.